Kyverna Therapeutics, Inc.

Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. The company engineers and manufactures autologous T cells with synthetic constructs to selectively target and modulate the immune system. Kyverna's approach aims to provide durable remissions for patients suffering from a range of autoimmune disorders, addressing significant unmet medical needs. By leveraging advanced T cell engineering, Kyverna is working to create a new class of therapies that offer improved efficacy and safety profiles compared to existing treatments. The company's research and development efforts are centered on advancing its pipeline of novel cell therapies through clinical trials and regulatory approval, with the goal of transforming the treatment landscape for autoimmune diseases.